NZ considers restrictions
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Medsafe’s Medicines Classification Committee (MCC) is set to discuss whether to further restrict access to modified-release paracetamol products in New Zealand, following a recommendation from the country’s Medicines Adverse Reactions Committee (MARC).